Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083165 | 0.85 | CYP2A6 (0.58) | CYP2A6ERN1RAB9AALDH1A1DYRK1A | |
| SCHEMBL30197462 | 0.85 | CYP2A6 (0.58) | CYP2A6ERN1RAB9AALDH1A1DYRK1A | |
| SCHEMBL29953847 | 0.77 | CYP2A6 (0.62) | CYP2A6MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL793305 | 0.77 | CYP2A6 (0.62) | CYP2A6MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL1397680 | 0.77 | CYP2A6 (1.00) | CYP2A6RAB9AALDH1A1DYRK1AAKR1B1 | |
| SCHEMBL3618744 | 0.77 | CYP2A6 (0.62) | CYP2A6ERN1ALDH1A1 | |
| SCHEMBL13659121 | 0.77 | CYP2A6 (0.62) | CYP2A6DYRK1A | |
| SCHEMBL12683402 | 0.77 | CYP2A6 (0.61) | CYP2A6 | |
| SCHEMBL15897439 | 0.74 | CYP2A6 (0.50) | CYP2A6 | |
| SCHEMBL29629031 | 0.74 | CYP2A6 (1.00) | CYP2A6ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111533696-A | Benzimidazole derivative, benzothiophene derivative, and preparation method and application thereof | 苏州大学 | 2020-08-14 | — | — | CN | disclosed |
| US-9592221-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592221-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| US-9315495-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315495-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150197512-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | PROVID PHARMACEUTICALS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197512-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | PROVID PHARMACEUTICALS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| EP-2049481-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | POLRMT, POLR1C, FBL | CYP2A6 941/4885HSP90AA1 1188/4885LMNA 1360/4885 |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | CYP2A6 3232/4885HSP90AA1 1778/4885LMNA 715/4885 |
| US-20150197512-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | FBL, POLRMT, POLR1C | CYP2A6 1098/4885HSP90AA1 1473/4885LMNA 514/4885 |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | CYP2A6 1871/4885HSP90AA1 3620/4885LMNA 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.